# Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

> **NCT00580034** · PHASE2 · COMPLETED · sponsor: **David Rizzieri, MD** · enrollment: 176 (actual)

## Conditions studied

- Lymphoma
- Myeloma
- Leukemia
- Myelodysplasia
- Solid Tumors

## Interventions

- **DRUG:** Campath Purged Non-myeloablative ASCT
- **PROCEDURE:** Donor Apheresis

## Key facts

- **NCT ID:** NCT00580034
- **Lead sponsor:** David Rizzieri, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2014-06-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00580034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00580034, "Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00580034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*